Compare
Amgen Inc vs Gilead Sciences, Inc. vs Biogen Inc. vs Neurocrine Biosciences Inc
| Latest fiscal year | Amgen Inc AMGN | Gilead Sciences, Inc. GILD | Biogen Inc. BIIB | Neurocrine Biosciences Inc NBIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $36.75B | $29.44B | $9.89B | $2.86B |
| Revenue growth (YoY) | +10.0% | +2.4% | +2.2% | +21.4% |
| Gross margin | 67.2% (computed) | 78.8% (computed) | 75.7% (computed) | n/a |
| Operating margin | 24.7% | 34.0% | n/a | 21.6% |
| Net margin | 21.0% | 28.9% | 13.1% | 16.7% |
| Net income | $7.71B | $8.51B | $1.29B | $478.60M |
| EPS (Diluted) | $14.23 | $6.78 | $8.79 | $4.67 |
| Operating cash flow | $9.96B | $10.02B | $2.20B | $782.70M |
| Free cash flow | $8.10B | $9.46B | $2.05B | $748.70M |
| Cash & equivalents | $9.13B | n/a | n/a | $713.00M |
| Total assets | $90.59B | $59.02B | $29.44B | $4.63B |
| Total liabilities | n/a | n/a | $11.18B | $1.38B |
| Shareholders' equity | $8.66B | $22.62B | $18.26B | $3.25B |
| Return on year-end equity | 89.1% | 37.6% | 7.1% | 14.7% |
| Shares outstanding | 538.80M | 1.24B | 146.80M | 100.10M |
Revenue, most recent five fiscal years
| Fiscal year | Amgen Inc | Gilead Sciences, Inc. | Biogen Inc. | Neurocrine Biosciences Inc |
|---|---|---|---|---|
| Latest | $36.75B Ended 2025-12-31 | $29.44B Ended 2025-12-31 | $9.89B Ended 2025-12-31 | $2.86B Ended 2025-12-31 |
| 1 year earlier | $33.42B Ended 2024-12-31 | $28.75B Ended 2024-12-31 | $9.68B Ended 2024-12-31 | $2.36B Ended 2024-12-31 |
| 2 years earlier | $28.19B Ended 2023-12-31 | $27.12B Ended 2023-12-31 | $9.84B Ended 2023-12-31 | $1.89B Ended 2023-12-31 |
| 3 years earlier | $26.32B Ended 2022-12-31 | $27.28B Ended 2022-12-31 | $10.17B Ended 2022-12-31 | $1.49B Ended 2022-12-31 |
| 4 years earlier | $25.98B Ended 2021-12-31 | $27.30B Ended 2021-12-31 | $10.98B Ended 2021-12-31 | $1.13B Ended 2021-12-31 |